Because of a preconceived notion that eliminating reactive metabolite (RM) formation with
new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM …

The overproduction of reactive oxygen species (ROS) and consequent oxidative stress
contribute to the pathogenesis of acute and chronic liver diseases. It is now acknowledged …

Numerous investigations have shown that mitochondrial dysfunction is a major mechanism
of drug-induced liver injury, which involves the parent drug or a reactive metabolite …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
Western countries and is considered the hepatic manifestation of metabolic syndrome. The …

Calorie-enriched diet and lack of exercise are causing a worldwide surge of obesity, insulin
resistance and lipid accretion in liver (ie hepatic steatosis), which can lead to steatohepatitis …

Non‐alcoholic fatty liver disease (NAFLD) represents a histological spectrum of liver disease
associated with obesity, diabetes and insulin resistance that extends from isolated steatosis …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein
receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver …

NONALCOHOLIC FATTY LIVER DISEASE is emerging as the most common chronic liver
condition in the Western world. It is associated with insulin resistance and frequently occurs …

Steatosis of the liver may arise from a variety of conditions, but the molecular basis for lipid
droplet formation is poorly understood. Although a certain amount of lipid storage may even …

A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive
metabolites that trigger hepatitis through direct toxicity or immune reactions. Both events …